Related Experiment Videos
Altered gene expression in immunogenic poorly differentiated thyroid carcinomas from RET/PTC3p53-/- mice.
D J Powell1, J P Russell, G Li
1Department of Microbiology/Immunology and Otolaryngology-Head & Neck Surgery, Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania, PA 19107, USA.
Oncogene
|June 26, 2001
Summary
Thyroid cancer progression involves RET/PTC3, p53, and Fhit genes. Loss of p53 and Fhit, along with reduced RET/PTC3, drives aggressive thyroid tumors in mice.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Cancer development involves oncogene activation and tumor suppressor gene loss.
- Mouse models are crucial for studying thyroid carcinogenesis mechanisms.
Purpose of the Study:
- To investigate the roles of RET/PTC3, p53, and Fhit in thyroid cancer.
- To elucidate the genetic pathways driving thyroid tumor progression.
Main Methods:
- Intercrossing RET/PTC3 transgenic mice with p53 knockout mice (p53-/-).
- Analyzing tumor development, growth in immunocompromised (SCID) and immunocompetent mice.
- Assessing RET/PTC3 and Fhit protein expression in tumors.
Main Results:
- RET/PTC3p53-/- mice developed large, aggressive thyroid tumors.
- Tumors from RET/PTC3p53-/- mice were immunogenic.
- Reduced RET/PTC3 and Fhit expression correlated with tumor progression.
- RET/PTC3Fhit-/- mice did not develop advanced thyroid carcinomas.
Conclusions:
- Thyroid cancer progression involves early RET/PTC3 expression, followed by p53 loss and Fhit reduction.
- RET/PTC3, p53, and Fhit play critical roles in thyroid carcinogenesis.
- A model for human thyroid cancer progression is proposed based on these genetic interactions.